{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Baseline CD4 T cell response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Post-immunization CD4 T-cell response/increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Baseline CD8 T cell response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Post-immunization CD8 T-cell response/increase"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Cellular immunity was determined by enzyme-linked immunosorbent spot assay (ELISPOT) or intracellular flow cytometry to determine peripheral blood levels of interferon gamma-producing CD4+ and CD8+ T cells specific for MAGE-A3. Results were considered significant if \\> 50 spots and \\> 2 times the number of spots to negative control were observed.","groups":[{"description":"Includes all subjects who received at least 1 immunization with study drug and had a baseline and at least 1 post-baseline immunity assessment.","id":"OG000","title":"Immunogenicity Analysis Set"}],"paramType":"NUMBER","populationDescription":"The Immunogenicity Analysis Set comprises all subjects who received at least 1 immunization with study drug and had a baseline and at least 1 post-baseline immunity assessment.","reportingStatus":"POSTED","timeFrame":"Baseline, first immunization, and first and second leukopheresis prior to auto-SCT; Days 31, 73, 194, 284, and 374 after auto-SCT","title":"Induction or Augmentation of MAGE-A3-Specific Cellular Immunity","type":"SECONDARY","unitOfMeasure":"participants"}